Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Masimo shareholders approve sale to Danaher

Masimo shareholders approve sale to Danaher

Money Moves
By Newzino Staff |

Stockholders back $180-per-share cash deal valuing the patient-monitoring firm at $9.9 billion, ending a four-year arc from activist takeover to strategic exit.

Yesterday: Masimo shareholders approve Danaher merger

Overview

Eighteen months after activist investor Politan Capital ousted Joe Kiani from the board of the medical-device company he founded in 1989, Masimo shareholders voted to sell the entire firm to industrial conglomerate Danaher for $9.9 billion. The tally was lopsided: roughly 37 million shares in favor, 17,061 against, and 14,035 abstaining.

Why it matters

A 9% activist stake just produced a $9.9 billion sale of a company whose monitors sit in nearly every U.S. hospital—reshaping who controls critical medical technology.

Key Indicators

$9.9B
Total deal value
Enterprise value including assumed debt, net of acquired cash.
$180
Per-share cash price
Each Masimo share converts to $180 in cash at closing.
99.95%
Shareholder approval
Roughly 37 million shares voted yes; only 17,061 voted against.
9%
Politan's original stake
Activist fund Politan Capital used a single-digit holding to win two board fights.
2
Proxy fights won by Politan
Activist won board seats in 2023 and 2024, ousting founder Joe Kiani.
H2 2026
Expected close
Subject to regulatory clearances and customary conditions.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Organizations Involved

Timeline

  1. Masimo shareholders approve Danaher merger

    Vote

    Masimo announces that stockholders overwhelmingly approved the merger agreement, with roughly 37 million shares in favor and only 17,061 against. The deal still requires regulatory clearance.

  2. Danaher announces $9.9 billion acquisition of Masimo

    Corporate Action

    Danaher agrees to buy Masimo for $180 per share in cash, valuing the company at approximately $9.9 billion including assumed debt. Masimo will join Danaher's Diagnostics segment.

  3. Sound United sale to Samsung's Harman closes

    Divestiture

    Masimo completes the $350 million sale of its Sound United consumer-audio business to Harman International, undoing the 2022 acquisition that triggered the activist campaign.

  4. Masimo wins $634 million verdict against Apple

    Legal

    A California federal jury awards Masimo $634 million on patent claims tied to Apple Watch heart-rate notification features, strengthening the IP value Danaher would later acquire.

  5. Katie Szyman named CEO

    Leadership

    Former BD and Edwards Lifesciences executive Katie Szyman takes over as Masimo CEO with a mandate to refocus the company on its medical-device core.

  6. Politan wins second proxy fight, ousts founder Kiani

    Governance

    Shareholders vote Joe Kiani off the Masimo board, electing Politan nominees Darlene Solomon and Bill Jellison instead. Kiani resigns as CEO days later.

  7. ITC bans certain Apple Watches over Masimo patents

    Legal

    The U.S. International Trade Commission orders an import ban on Apple Watch Series 6, 7, 8, and 9 models for infringing Masimo's pulse oximetry patents, validating the company's IP portfolio.

  8. Politan wins first proxy fight

    Governance

    Shareholders elect Koffey and healthcare veteran Michelle Brennan to the Masimo board over management's preferred slate.

  9. Politan Capital discloses ~9% Masimo stake

    Activist Campaign

    New York activist fund Politan Capital, run by Quentin Koffey, surfaces as a major Masimo shareholder, citing the destruction of value from the Sound United deal.

  10. Masimo announces $1 billion Sound United acquisition

    Corporate Action

    Masimo agrees to buy consumer-audio company Sound United, parent of Denon, Marantz, and Bowers & Wilkins. The pivot away from medical devices stuns investors and the stock falls more than 35% in the following months.

Scenarios

1

Deal closes on schedule in second half of 2026

Discussed by: Danaher management; Kirkland & Ellis (deal counsel); analysts at Stifel and Leerink

The shareholder vote was the largest remaining hurdle. With antitrust review of two complementary—not overlapping—diagnostics businesses unlikely to face serious objection, the transaction closes in Q3 or Q4 2026 as Danaher has guided. Masimo becomes a standalone operating company inside Danaher's Diagnostics segment, and Danaher books the projected $125 million in annual cost synergies starting in year five.

2

Antitrust review extends timeline into 2027

Discussed by: Antitrust attorneys tracking healthcare consolidation; Federal Trade Commission watchers

Although Masimo's pulse oximetry doesn't directly overlap with Danaher's existing diagnostics lines, regulators have grown more skeptical of large healthcare deals. A second-request from the Department of Justice or FTC could push closing into 2027, force minor divestitures, or impose behavioral conditions on hospital pricing—but is unlikely to block the deal outright.

3

Apple litigation complicates integration

Discussed by: Patent litigation reporters; Apple Insider; Fierce Biotech

Masimo's ongoing patent battles with Apple—including the $634 million 2025 verdict and continuing import-ban proceedings—pass to Danaher at closing. A reversal at the Federal Circuit, settlement, or new countersuit could materially change the value of Masimo's IP portfolio post-close, though the core hospital monitoring business is unaffected by the consumer-watch dispute.

Historical Context

Whole Foods sold to Amazon after Jana Partners pressure (2017)

April–August 2017

What Happened

Activist fund Jana Partners disclosed an 8.8% stake in Whole Foods in April 2017, criticized management, and pushed for a sale or operational overhaul. Within ten weeks, Amazon agreed to buy the grocer for $13.7 billion at a 27% premium. The deal closed in August 2017.

Outcome

Short Term

Whole Foods shareholders received a substantial premium; founder John Mackey stayed on briefly before retiring. Jana Partners exited with sizable gains.

Long Term

The deal demonstrated how a single-digit activist stake could trigger a billion-dollar sale of a founder-led company to a strategic acquirer, becoming the template playbook later imitated at Masimo and elsewhere.

Why It's Relevant Today

Same mechanism: minority activist stake creates board pressure, founder loses control, company sells to a deep-pocketed strategic buyer at a premium. Politan executed the longer-cycle version of the Jana playbook.

Forest Laboratories sold to Actavis after Icahn campaign (2014)

February 2014

What Happened

Carl Icahn took a roughly 11% stake in Forest Labs in 2011 and ran two proxy fights against the founding Solomon family, eventually winning four board seats. In February 2014, Forest agreed to sell to Actavis for $25 billion, with Icahn's stake worth approximately $1.7 billion at the deal price.

Outcome

Short Term

Founder Howard Solomon's son Andrew, who had been groomed as successor, never took over. Forest's specialty-pharma franchise was absorbed into Actavis.

Long Term

Actavis later became Allergan, then was acquired by AbbVie in 2020 for $63 billion, putting Forest's assets through three owners in six years—a cautionary case for how activist-driven sales can accelerate further consolidation.

Why It's Relevant Today

Closest medical-industry parallel: minority activist holding (~10%), multiple proxy fights, founder family ousted, strategic sale at a large premium. The Masimo sequence compresses essentially the same script.

Sources

(11)